Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CTEP
- Development stage
- Preclinical
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CTEP is a **research drug** developed by Hoffmann-La Roche that acts as a **selective allosteric antagonist** of the **metabotropic glutamate receptor subtype 5 (mGluR5)**. It binds with nanomolar affinity and shows over 1000-fold selectivity over other receptor targets tested. In animal studies, CTEP demonstrates high oral bioavailability and a long duration of action (lasting up to 18 hours after single dose), making it an improvement over earlier mGluR5 antagonists such as MPEP and fenobam. Its principal use is as a research tool in central nervous system studies, particularly for disorders related to glutamatergic signaling[1].
- Other names
- Ro4956371Ro-4956371Ro 4956371
02
Targets
GRM5 (Metabotropic glutamate receptor 5)
Beyond the preview
Go deeper on CTEP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CTEP.